Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1978 Aug;33(2):204–210.

DNA-binding antibodies and hepatitis B markers in acute and chronic liver disease.

J G Kingham, S Rassam, N Ganguly, M J Mcguire, B Nasrat, S T Holgate, D R Triger, R Wright
PMCID: PMC1537574  PMID: 309808

Abstract

A Farr technique has been used to assay antibodies to double-stranded DNA in the serum of patients with acute and chronic liver disease and carriers of HBsAg from the United Kingdom and Iraq. These antibodies were found in all groups from both countries. The highest levels were found in chronic active hepatitis and cirrhosis. In the Iraqi patients there was a strongly positive correlation between DNA-binding antibody levels and the presence of hepatitis B markers but not with disease activity. In the patients from the United Kingdom there was little correlation with disease activity and none with autoantibodies. Ninety-five per cent of asymptomatic carriers of HBsAG had elevated DNA-binding antibodies. It is suggested that hepatitis B-specific DNA might be one trigger to DNA antibody formation, though in liver disease a variety of factors are clearly operative.

Full text

PDF
204

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carr R. I., Koffler D., Agnello V., Kunkel H. G. Studies on DNA antibodies using DNA labelled with actinomycin-D (3H) or dimethyl (3H) sulphate. Clin Exp Immunol. 1969 May;4(5):527–536. [PMC free article] [PubMed] [Google Scholar]
  2. Davis P., Read A. E. Antibodies to double-stranded (native) DNA in active chronic hepatitis. Gut. 1975 Jun;16(6):413–415. doi: 10.1136/gut.16.6.413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gershwin M. E., Glinski W., Bender A. N., Ringel S. P., Steinberg A. D., Engel W. K. Antibodies to nucleic acids in myasthenia gravis. Int Arch Allergy Appl Immunol. 1976;51(2):245–252. doi: 10.1159/000231597. [DOI] [PubMed] [Google Scholar]
  4. Hughes G. R. Significance of anti-D.N.A. antibodies in systemic lupus erythematosus. Lancet. 1971 Oct 16;2(7729):861–863. doi: 10.1016/s0140-6736(71)90234-0. [DOI] [PubMed] [Google Scholar]
  5. Hung P. P., Mao J. C., Ling C. M., Overby L. R. Hybridisation of Dane particle DNA with the free plasma DNA of hepatitis carriers. Nature. 1975 Feb 13;253(5492):571–572. doi: 10.1038/253571a0. [DOI] [PubMed] [Google Scholar]
  6. Jain S., Markham R., Thomas H. C., Sherlock S. Double-stranded DNA-binding capacity of serum in acute and chronic liver disease. Clin Exp Immunol. 1976 Oct;26(1):35–41. [PMC free article] [PubMed] [Google Scholar]
  7. Pincus T., Schur P. H., Rose J. A., Decker J. L., Talal N. Measurement of serum DNA-binding activity in systemic lupus erythematosus. N Engl J Med. 1969 Sep 25;281(13):701–705. doi: 10.1056/NEJM196909252811304. [DOI] [PubMed] [Google Scholar]
  8. Sherlock S. Chronic hepatitis. Gut. 1974 Jul;15(7):581–597. doi: 10.1136/gut.15.7.581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Sherlock S., Scheuer P. J. The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med. 1973 Sep 27;289(13):674–678. doi: 10.1056/NEJM197309272891306. [DOI] [PubMed] [Google Scholar]
  10. Steinberg A. D., Pincus T., Talal N. DNA-binding assay for detection of anti-DNA antibodies in NZB-NZW F1 mice. J Immunol. 1969 Mar;102(3):788–790. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES